EUVIMEDEUVIMED entdecken
Crossref

Synergism between remdesivir and ribavirin leads to SARS‐CoV‐2 extinction in cell culture

Carlos García-Crespo, Ana Isabel de Ávila, Isabel Gallego, María Eugenia Soria, Antoni Durán-Pastor, Pilar Somovilla, Brenda Martínez-González, Javier Muñoz-Flores, Pablo Mínguez, Llanos Salar-Vidal, Mario Esteban-Muñoz, Elizabeth Cañar-Camacho und 11 weitere

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Carlos García-Crespo und 22 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Biología Molecular Severo Ochoa (CBM), CSIC-UAM, Campus de Cantoblanco, Madrid, Spain. Hauptthemen laut MEDLINE: Alanine, Ribavirin, Antiviral Agents, Adenosine Monophosphate. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: Consejería de Educación e Investigación, Ministerio de Ciencia e Innovación, Consejo Superior de Investigaciones Científicas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose There is a need for effective anti‐COVID‐19 treatments, mainly for individuals at risk of severe disease such as the elderly and the immunosuppressed. Drug repositioning has proved effective in identifying drugs that can find a new application for the control of coronavirus disease, in particular COVID‐19. The purpose of the present study was to find synergistic antiviral combinations for COVID‐19 based on lethal mutagenesis. Experimental Approach The effect of combinations of remdesivir and ribavirin on the infectivity of SARS‐CoV‐2 in cell culture has been tested. Viral populations were monitored by ultra‐deep sequencing, and the decrease of infectivity as a result of the treatment was measured. Key Results Remdesivir and ribavirin exerted a synergistic inhibitory activity against SARS‐CoV‐2, quantified both by CompuSyn (Chou‐Talalay method) and Synergy Finder (ZIP‐score model). In serial passage experiments, virus extinction was readily achieved with remdesivir‐ribavirin combinations at concentrations well below their cytotoxic 50 value, but not with the drugs used individually. Deep sequencing of treated viral populations showed that remdesivir, ribavirin, and their combinations evoked significant increases of the number of viral mutations and haplotypes, as well as modification of diversity indices that characterize viral quasi‐species. Conclusion and Implications SARS‐CoV‐2 extinction can be achieved by synergistic combination treatments based on lethal mutagenesis. In addition, the results offer prospects of triple drug treatments for effective SARS‐CoV‐2 suppression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlanineRibavirinAntiviral AgentsAdenosine MonophosphateDrug SynergismSARS-CoV-2Chlorocebus aethiopsVero CellsAnimalsHumansCOVID-19 Drug TreatmentCOVID-19

Stichwörter der Autor:innen

COVID‐19 therapyQuasi‐specieserror catastrophelethal mutagenesisvirus diversity

Substanzen

AlanineremdesivirRibavirinAntiviral AgentsAdenosine Monophosphate

Autor:innen und Institutionen

  • Centro de Biología Molecular Severo Ochoa (CBM), CSIC-UAM, Campus de Cantoblanco, Madrid, Spain.
  • Department of Clinical Microbiology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
  • Department of Molecular and Cell Biology, Centro Nacional de Biotecnología (CNB-CSIC), Consejo Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, Madrid, Spain.
  • Departamento de Biología Molecular, Universidad Autónoma de Madrid, Campus de Cantoblanco, Madrid, Spain.
  • GMS Management Solutions S.L., Torre Picasso, Madrid, Spain.
  • Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.

Förderung

  • Consejería de Educación e Investigación
  • Ministerio de Ciencia e Innovación
  • Consejo Superior de Investigaciones Científicas
  • Ministerio de Ciencia, Innovación y Universidades
  • Instituto de Salud Carlos III
  • Fundació La Marató de TV3

Zitieren

APA

García-Crespo, C., de Ávila, A. I., Gallego, I., Soria, M. E., Durán-Pastor, A., Somovilla, P., Martínez-González, B., Muñoz-Flores, J., Mínguez, P., Salar-Vidal, L., Esteban-Muñoz, M., Cañar-Camacho, E., Ferrer-Orta, C., Zuñiga, S., Sola, I., Enjuanes, L., Esteban, J., Fernández-Roblas, R., Gadea, I., …, & Perales, C. (2024). Synergism between remdesivir and ribavirin leads to SARS‐CoV‐2 extinction in cell culture. British Journal of Pharmacology. https://doi.org/10.1111/bph.16344

Vancouver

García-Crespo C, de Ávila AI, Gallego I, Soria ME, Durán-Pastor A, Somovilla P, et al. Synergism between remdesivir and ribavirin leads to SARS‐CoV‐2 extinction in cell culture. British Journal of Pharmacology. 2024. doi:10.1111/bph.16344

BibTeX
@article{GarcaCrespo2024,
  author = {García-Crespo, Carlos and de Ávila, Ana Isabel and Gallego, Isabel and Soria, María Eugenia and Durán-Pastor, Antoni and Somovilla, Pilar and Martínez-González, Brenda and Muñoz-Flores, Javier and Mínguez, Pablo and Salar-Vidal, Llanos and Esteban-Muñoz, Mario and Cañar-Camacho, Elizabeth and Ferrer-Orta, Cristina and Zuñiga, Sonia and Sola, Isabel and Enjuanes, Luis and Esteban, Jaime and Fernández-Roblas, Ricardo and Gadea, Ignacio and Gómez, Jordi and Verdaguer, Nuria and Domingo, Esteban and Perales, Celia},
  title = {Synergism between remdesivir and ribavirin leads to SARS‐CoV‐2 extinction in cell culture},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16344}
}
Kostenlos starten →